SecBot SecBot
8-K ·Filed Nov 9, 2026

DCTH

DELCATH SYSTEMS, INC.
BULLISH
Impact 6/10
Horizonweeks Processed7d 18h ago SEC0001628280-26-071894
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The raised guidance and accelerating HEPZATO volume growth (72% YoY) suggest strong commercial momentum. Watch for continued center expansion and the DELUMA Phase 2 breast cancer trial enrollment updates. The activist presence (9.9% stake) may push for further operational or strategic initiatives.

DirectionBullish
Confidencehigh
Horizonweeks

HEPZATO KIT

▲ Bullish Named in this 8-K
Impact
Phase
Approved (FDA)
Time to market
Already on the market. FDA-approved August 2023, currently generating commercial revenue.
Next catalyst
None dated

What to watchWith no binary FDA catalyst ahead, the stock's near-term direction hinges on commercial execution: watch Q4 2026 earnings (expected early 2027) for continued HEPZATO KIT revenue growth and treatment center expansion. The Phase 2 breast cancer trial is an important long-term value driver but is unlikely to produce pivotal data within 12 months. The stock's 52-week high near $22.32 and strong institutional accumulation suggest the market is already pricing in the current growth trajectory.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+5
Entry
$20.27
T+0 close · Nov 9, 2026 · via day close
Latest settled
−1.97%
T+5 · $19.87
Vs SPY
−0.28%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $20.27entry
  2. T+1 · 7d ago −0.84%α −0.47% · $20.10
  3. T+5 · 20h ago −1.97%α −0.28% · $19.87
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Delcath Systems reported Q3 2026 revenue of $35.1M (vs. $25.8M consensus) and GAAP EPS of $0.17 (vs. $-0.08 consensus), a strong beat. The company raised its full-year 2026 revenue guidance to $115M-$117M, reflecting at least 41% HEPZATO volume growth over 2025. The activist investor (Rosalind Advisors, 9.9% stake) filed an amended 13D 21 days prior, adding pressure for continued execution.

Key Financial Metrics

EPS
$0.17
est −$0.08 · +312.5%
Revenue
$35.1M
est $25.8M · +36.0% · +70.7% YoY
Rating
strong beat
Guidance
$115M-$117M
raised
Gross Margin
89%

Key Facts

  • Q3 2026 total revenue $35.1M, up 71% from $20.6M in Q3 2025
  • GAAP diluted EPS $0.17 vs. consensus estimate of $-0.08
  • HEPZATO KIT revenue $32.7M, up 69% from $19.3M in Q3 2025
  • Full-year 2026 revenue guidance raised to $115M-$117M from prior at least $100M
  • Gross margin improved to 89% from 87% in Q3 2025
  • Net income $7.0M vs. $0.8M in Q3 2025; positive adjusted EBITDA $11.5M
  • Cash and investments $104.3M, no debt
  • 33 active treatment centers vs. 29 in Q1 2026; HEPZATO volume grew ~72% YoY
  • Activist Rosalind Advisors holds 9.9% stake (SC 13D/A filed Oct 19, 2026)

Financial Impact

Revenue beat consensus by 36% ($35.1M vs. $25.8M); EPS beat consensus by $0.25; guidance raised by $15M-$17M at midpoint

revenueepsgross marginguidance

Segment Breakdown

SegmentRevenueGrowth
HEPZATO KIT (U.S.)$32.7M+69.4%
CHEMOSAT (Europe)$2.4M+84.6%

Risk Factors

  • Dependence on HEPZATO KIT adoption and treatment center expansion
  • Clinical trial costs (R&D $11.0M, up 38% YoY) may pressure margins
  • Competition from other liver-directed therapies
  • Regulatory and reimbursement risks for HEPZATO KIT

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
92% bullish (12 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-071894
Document: dcth-20261109.htm0001628280-26-071894
Document: 0001628280-26-071894-index-headers.html0001628280-26-071894
Document: 0001628280-26-071894-index.html0001628280-26-071894
Document: 0001628280-26-071894.txt0001628280-26-071894
8-K Data (Synthetic)0001628280-26-071894

Track record

12 reports on DCTH

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +27.22% at T+60 after the Feb 26, 2026 report. 3 of 3 went positive at some point.

Filters
  1. Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $21.38 Now $19.87 −7.06% settles Feb 10
  2. Nov 9, 20267d ago 8-K Bullish 6/10 Viewing Entry $20.27 Now $19.87 −1.97% settles Feb 5
  3. Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $14.82 Now $19.87 +34.08% settles Feb 2
  4. Oct 27, 202620d ago SC 13G Neutral 3/10 Entry $14.86 Now $19.87 +33.71% settles Jan 26
  5. Oct 19, 202628d ago SC 13D/A Neutral 4/10 Entry $14.37 Now $19.87 +38.27% settles Jan 14
  6. Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $11.77 to $16.48 Now $19.87 +68.89% ▲ +40.08% +35.68% vs SPY
  7. May 14, 202626w ago 8-K Neutral 3/10 Entry $11.46 to $16.67 Now $19.87 +73.39% ▲ +45.46% +41.87% vs SPY
  8. May 7, 202627w ago 8-K Neutral 5/10 Entry $11.24 to $13.04 Now $19.87 +76.78% ▲ +16.01% +12.18% vs SPY
  9. Apr 2, 202632w ago DEFA14A Neutral 3/10 Entry $9.63 to $12.59 Now $19.87 +106.33% ▲ +30.74% +16.58% vs SPY
  10. Mar 2, 202637w ago Insider Cluster Bullish 6/10 Entry $8.93 to $10.83 Now $19.87 +122.51% ▲ +21.28% +11.95% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens in 6h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026